Mathieu Kuchenbuch

Mathieu Kuchenbuch

Auto-generated profile, based on publicly available information

Mathieu Kuchenbuch

Department of Pediatrics, Reference Center for Rare Epilepsies, member of the European Reference Network EpiCARE, University Hospital of Nancy, Nancy, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
RNRima Nabbout
Rima Nabbout
MKMathieu Kuchenbuch
Mathieu Kuchenbuch

29 August 2019 in Brain
Verified
Journal Article
Closed access
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
GBGiulia Barcia
Giulia Barcia
NCNicole Chemaly
Nicole Chemaly
ECEmilie Carme
Emilie Carme
ARAgathe Roubertie
Agathe Roubertie
RNRima Nabbout
Rima Nabbout
Data on KCNT1 epilepsy of infancy with migrating focal seizures are heterogeneous and incomplete. Kuchenbuch et al. refine the syndrome phenotype, showing a three-step temporal sequence, poor prognosis with acquired microcephaly, high prevalence of extra-neurological manifestations and early mortality, particularly due to SUDEP. Refining the electro-clinical spectrum should facilitate early diagnosis.

21 September 2020 in Epilepsia
Verified
Journal Article
Closed access
PDF file
CBClaire Bar
Claire Bar
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
GBGiulia Barcia
Giulia Barcia
ASAmy Schneider
Amy Schneider
MJMélanie Jennesson
Mélanie Jennesson
RNRima Nabbout
Rima Nabbout

4 June 2020 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
GDGianluca D'Onofrio
Gianluca D'Onofrio
NCNicole Chemaly
Nicole Chemaly
GBGiulia Barcia
Giulia Barcia
TTThéo Teng
Théo Teng
RNRima Nabbout
Rima Nabbout
Mutations in SYNGAP1 are associated with developmental delay, epilepsy, and autism spectrum disorder (ASD). Epilepsy is often drug‐resistant in this syndrome with frequent drop attacks. In a prospective study of add‐on cannabidiol (CBD), we identified three patients with SYNGAP1 mutations: two boys and one girl. Seizure onset was at 3.5, 8, and 18 months (M), respectively, with numerous atypical absences per day associated with eyelid myoclonia (2/3 patients), upper limb myoclonic jerks (2/3 patients), and drop attacks (all patients). Seizures were resistant to at least 5 antiepileptic drugs (AEDs). After CBD introduction, two patients were responders since M2 and achieve a seizure reduction of 90% and 80%, respectively, at M9 with disappearance of drop attacks. EEGs showed an improvement regarding background activity and interictal anomalies. The last patient showed a late response at M7 of treatment with an 80% decrease in seizure frequency. Caregiver in all three evaluated as much improved the status of their children. Treatment was well‐tolerated in all, and no major adverse events (AEs) were reported. CBD showed efficacy in patients with drug‐resistant epilepsy due to SYNGAP1 mutations. Other patients with rare genetic developmental and epileptic encephalopathies with drug‐resistant epilepsies might benefit from CBD.

1 November 2020 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
GDGianluca D'ONofrio
Gianluca D'ONofrio
EWElaine Wirrell
Elaine Wirrell
YJYuwu Jiang
Yuwu Jiang
SDSophie Dupont
Sophie Dupont
RNRima Nabbout
Rima Nabbout

7 December 2018 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
PBPascal Benquet
Pascal Benquet
AKAnna Kaminska
Anna Kaminska
ARAgathe Roubertie
Agathe Roubertie
ECEmilie Carme
Emilie Carme
RNRima Nabbout
Rima Nabbout